ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer

ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer

Despite initial benefits in treating HER2-positive breast cancer patients with lapatinib, resistance is prevalent. Here the authors show that lapatinib resistance can be ascribed to mTOR-mediated re-activation of ERRα and to the consequent induction of a metabolic adaptation.

Bibliographic Details
Main Authors: Geneviève Deblois, Harvey W. Smith, Ingrid S. Tam, Simon-Pierre Gravel, Maxime Caron, Paul Savage, David P. Labbé, Louis R. Bégin, Michel L. Tremblay, Morag Park, Guillaume Bourque, Julie St-Pierre, William J. Muller, Vincent Giguère
Format: Article
Language:English
Published: Nature Publishing Group 2016-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/ncomms12156

Internet

https://doi.org/10.1038/ncomms12156

Similar Items